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Abstract 
 
Objective  
To evaluate the fatty acid profile of cord blood phospholipids (PL), cholesteryl esters (CE), triglycerides (TG) 
and non-esterified fatty acids (NEFA) in neonates born to mothers with gestational diabetes mellitus (GDM) 
compared to non-diabetic mothers.  
Methods  
The offspring of 30 pregnant women (15 non-diabetic controls, 15 with diet- or insulin-controlled GDM) were 
recruited before delivery. Cord blood was collected. After lipid extraction, PL, CE, TG and NEFA were 
separated by thin layer chromatography and analysed by gas chromatography.  
Results  
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In GDM vs. control mothers, maternal glycated haemoglobin (A1C, mean ± SD) was not different between 
groups: 5.3 ± 0.5% vs. 5.3 ± 0.3% (p = 0.757), respectively. Cord plasma fatty acids were not different in TG, 
CE and NEFA between GDM and non-diabetic mothers. However, in PL, levels of palmitate, palmitoleate, 
oleate, vaccinate and di-homo-gamma-linolenate were significantly lower, with a trend for lower arachidonate 
(p = 0.078), in neonates born to GDM mothers compared to controls.  
Conclusion 
In contrast to other studies on cord blood docosahexaenoic acid (DHA) levels in GDM mothers, we did not 
found lower levels of DHA in cord PL, CE, TG or NEFA in neonates born to GDM compared to non-diabetic 
mothers.  
 
Abbreviation  
DHA, docosahexaenoic acid; GDM, gestational diabetes mellitus; PL, phospholipids; CE, cholesteryl esters, 
TG, triglycerides; NEFA, non-esterified fatty acids; A1C glycated haemoglobin; MUFA, monounsaturated fatty 
acids. 
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1. Introduction  
Gestational diabetes mellitus (GDM) is a state of glucose intolerance diagnosed during pregnancy. 
GDM affects 5 to 20 % of pregnant women, depending on screening/diagnosis methods and ethnicity [1]. It is 
suggested that some children born to mothers with poor glucose control during pregnancy suffer lower 
behavioral and intellectual development compared to children born to non-diabetic women [2, 3]. A key fatty 
acid for healthy brain and nervous system development during pregnancy is docosahexaenoic acid (DHA). A 
DHA deficiency during this period might minimize neurodevelopment [4]. In humans, DHA is not efficiently 
synthesized by shorter-chain omega-3 fatty acids to fulfill the needs in DHA in the third trimester; so it has to 
be provided by dietary fat intake and transferred to the fetus via cord blood [5].  
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There is increasing evidence supporting that GDM modifies maternal fatty acid profile, which may in turn 
change the quantity/quality of lipids transferred to the fetus [6, 7]. To our knowledge, 9 case-control studies 
[8-16] evaluated DHA levels in cord blood of neonates born to GDM vs. non-diabetic mothers. Seven studies 
reported that DHA levels in cord blood were 12-36% lower in GDM vs. non-diabetic mothers. Most of these 
studies have evaluated DHA levels in phospholipids (PL), cholesteryl esters (CE) or in red blood cells 
although it is speculated that DHA in the non-esterified fatty acid (NEFA) pool is the preferred pool for 
reaching the brain for brain DHA accretion. We sought to evaluate the fatty acid profile and DHA in cord 
plasma PL, CE, triglycerides (TG) as well as in NEFA, in cord blood of neonates born to mothers with GDM 
compared to non-diabetic controls. 
 
2. Material and Method  
2.1. Population  
Pregnant women (n = 30, aged 18 - 40 years, with singleton pregnancy) were recruited in the Centre 
Hospitalier Universitaire de Sherbrooke at 24 - 28 weeks of gestation between December 2013 and May 2014. 
Exclusion criteria were: smoking, illicit drug or omega-3/6 consumption, liver or renal disease, cancer, or any 
medical condition affecting glucose/lipid metabolism. GDM diagnosis and management were performed 
according to ADA criteria [17]. Individualized insulin therapy was initiated if dietary modification, physical 
activity, and self-monitoring of blood failed to control glycemic levels [17]. 
 
2.2. Sample size 
The sample size (n = 12/group) was calculated considering that esterified DHA in cord plasma was 
17% lower in GDM group vs. non-diabetic mothers [14], and anticipating a 20% withdrawal rate in both 
groups. 
 
2.3. Ethic statement  
The study was approved by the Human Ethics Research Committee of the Centre Hospitalier 
Universitaire de Sherbrooke; women gave informed written consent for themselves and their newborn. 
 
2.4. Data collection  
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Maternal weight was measured close to delivery and BMI was calculated. Blood samples for maternal 
A1C were drawn at hospital admission, before delivery. At delivery, 3 ml of cord blood was collected, 
centrifuged, aliquoted, and stored at -80°C. Birth weight, length, head circumference, APGAR score and 
glycaemia were recorded. 
 
2.5. Blood sample analyses 
Maternal A1C, (normal range 3.6-5.8%) was measured using HPLC (Bio-Rad VARIANT, Hercules, 
CA) in the Biochemistry lab of the Centre Hospitalier Universitaire de Sherbrooke. Total lipids from the cord 
plasma were extracted and separated into PL, TG, CE and NEFA by thin layer chromatography. NEFA were 
thereafter transmethylated using 14% methanol-boron trifluoride before being analysed by gas 
chromatography, as we previously described [18]. Cord plasma glucose, total cholesterol, total TG and total 
NEFA were measured using an automated analyzer (Dimension Xpand Plus; Siemens Healthcare Diagnostics, 
Deerfield, IL). Insulin was measured using an immunosorbent assay (Alpco, Salem, NH). 
 
2.6. Statistical analysis  
Normal distribution was evaluated using the Kolmogorov-Smirnov test. Chi-square tests were used to 
test the differences in the proportions for the categorical variables and t-tests or Mann or Whitney tests were 
used to compare means between the groups (SPSS software, version 12.0; SPSS Inc., Chicago, IL). Two-tailed 
p value < 0.05 was considered statistically significant.  
 
3. Results 
3.1. Mothers and newborns characteristics 
Age, weight and BMI close to delivery were not different between groups (Table 1). A1C was identical 
(p = 0.757) and in the normal range in both groups (Table 1). In newborns, clinical characteristics were not 
different between group except for gestational age (38.1 ± 1.4 vs. 39.6 ± 1.3; p = 0.007) (Table 1). In cord 
plasma, glucose, insulin, total cholesterol, TG, and total NEFA were not different between groups.  
 
3.2 Fatty acid profile in the cord plasma PL, TG, CE and NEFA 
GDM mothers had 15-27% lower C16:0, C16:1 n-7, C18:1 n-9, C18:1 n-7 and C20:3 n-6 in the PL 
compared to non-diabetic mothers (Table 2). We also found a trend for lower C20:4 n-6 in cord PL of neonates 
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born to GDM vs. controls. The fatty acid profiles in cord NEFA, TG and CE were not different between 
groups (Table 2 and Table 3).  
 
4. Discussion and conclusions 
This study reports that newborns from mothers with optimally-controlled GDM received similar 
concentrations of esterified and non-esterified DHA. In GDM mothers, blood glucose over the last weeks of 
pregnancy was indeed well controlled in both groups as demonstrated by A1C levels that fall into the normal 
range. This suggests that glucose control in the last months of gestation plays a role in DHA level transferred 
to the newborn during gestation.   
The role of glucose control on the quantity/quality of most fatty acids transferred to the fetus is yet not 
clear. In our study, the fatty acid profile in PL was impaired in neonates born to GDM mothers: 
Monounsaturated fatty acids (MUFA) such as C16:1n-7, C18:1n-9, and C18:1n-7 were significantly lower 
than in controls. This result seems to be specific to the PL class since there was no difference in the other lipid 
classes neither in the total lipids (data not shown). This latter result is in line with other published studies 
where MUFA in total lipids of the cord blood in neonate born to well-controlled GDM vs. control were not 
different [8, 9]. In one study, the MUFA levels were 11-21 % lower in GDM mothers compared to non-
diabetic mothers [19] while another study showed that the concentration of lysophospholipids, a class of 
phospholipids, were 20 % lower in GDM maternal serum compared to pregnant controls [15]. PL are structural 
lipids and can be used as biomarkers for dietary fatty acid intake. PL may although not be the best indicator of 
fatty acid that are readily available for placental transfer [20]. In neonates, palmitic, palmitoleic, and oleic 
acids are concentrated in brain membrane: their concentrations increase in the plasma PL and NEFA from 
birth to 6-8 hrs of age [21]. Moreover the cerebral white matter is particularly rich in n-9 MUFA [22].  
We also report here that there was no difference in the esterified or non-esterified pool of DHA in 
neonates of women with well-controlled GDM vs. non-diabetic mothers. Our results are in line with two 
studies conducted in GDM [8, 23]. One of the paper reported that % DHA in the PL relative to other fatty 
acids was lower compared to control (2.9% vs 3.5%, P = 0.01) but this result became not significant after 
adjustment for confounding factors such as ethnicity, parity, pre-pregnancy BMI, smoking and alcohol use [9]. 
Ortega-Senovilla et al. studied the venous and arterial lipid profiles in cord blood of offspring from GDM. In 
arterial cord plasma of GDM, % DHA and ARA was 27% and 17% lower than in the control mothers but there 
was no difference in venous cord plasma [24]. There are two ways to interpret this finding: either the fetus 
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metabolizes more DHA, hence lowering the level of DHA in arterial cord blood, either DHA transfer to the 
fetus is disrupted. In line with this latter hypothesis, one study recently evaluated the transfer of DHA from the 
mothers’ blood to the fetus using uniformly labelled carbon 13 [
13
C]DHA in GDM vs. non-diabetic mothers 
[25]. This study supports the idea that placental DHA uptake is impaired in mothers with GDM whereas the 
transfer of the other fatty acids are less affected. Another study supporting this hypothesis evaluated the major 
facilitator super family domain containing 2a (Mfsd2a) transporter in the placenta of mothers with GDM 
compared to non-diabetic mothers. This transporter is described as being a lyso-phosphatidylcholine 
transporter required for brain DHA uptake [26]. It was shown that placenta Mfsd2a transporter levels was 
lower in GDM compared to non-diabetic mothers supporting that diabetic pregnancies is a medical condition 
that might influence the level of long chain fatty acid transporters in the placenta, hence disrupting DHA 
transport from the mother to the fetus.  
The respective biological role of esterified and non-esterified DHA is currently debated. While some 
believe that DHA needs a specific transporter, others are reporting data on the importance of the non-esterified 
DHA pool as a very important pool for brain DHA accretion during the third trimester of gestation [4]. This 
hypothesis is supported by measurements of DHA in the NEFA in various designs: cell membranes, in vitro 
studies, study using intravenous non-esterified radiolabeled DHA bound to albumin, and studies of in situ 
cerebral perfusion with 
14
C-DHA (reviewed in [27]). In our study, we found that the concentration of non-
esterified DHA in cord blood of neonates born to GDM vs. non-diabetic mothers varies between 1.3 and 2.9 
mg/dL, with no difference between groups.  
The selection criteria are one of the strengths of our study: mothers with confounding factors such as 
alcohol, tobacco consumption and omega-3 fatty acid supplementation were excluded. Moreover, we are the 
first to report the fatty acid profile in all lipid classes. The small size of our groups is the weakness of our 
study.   
In conclusion, our results suggest that the control of blood glucose during pregnancy in women with 
GDM is potentially sufficient to provide equivalent esterified and non-esterified DHA levels in cord blood 
although some fatty acids are significantly lower in the phospholipids of GDM mothers compared to control.  
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Summary 
Docosahexaenoic acid (DHA) is essential for neurodevelopment. We aimed to evaluate whether DHA status, 
in the esterified and non-esterified class of lipids in the cord blood, was modified in women with gestational 
diabetes mellitus (GDM) compared to non-diabetic women. Our results showed that GDM was optimally 
controlled, that the phospholipid profile was slightly modified in cord blood of neonates born to GDM, while 
DHA was not different between groups. Hence, in GDM women with optimal control of blood glucose during 
pregnancy, DHA levels were not different than control women.  
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Table 1: Characteristics of mothers and newborns 
  n 
Controls  
(n = 15) 
n 
GDM 
(n = 15) 
p value  
Maternal characteristics 
     
    Age (years) 15 27.9 ± 4.3 15 30.9 ± 5.2 0.102 
    Weight close to delivery (kg) 15 84.5 ± 18.0 15 90.4 ± 18.0 0.378 
    Weight gain (kg) 15 14.8 ± 8.3 15 15.3 ± 5.3 0.835 
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    BMI close to delivery (kg/m
2
) 15 31.1 ± 7.1 15 33.3 ± 6.1 0.381 
    A1C at delivery (%) 13 5.3 ± 0.3 15 5.3 ± 0.5 0.757 
    Caesarean section, n (%) 15 2 (7) 15 5 (17) 0.390 
 
Newborns characteristics      
    Sex ratio (boy/girl), n 15 9/6 15 8/7 0.999 
    Gestational age (weeks) 15 39.6 ± 1.3 15 38.1 ± 1.4 0.007 
    Birth weight (g) 15 3442 ± 346 15 3213 ± 479 0.145 
    Length (cm)   15 51.5 ± 1.7 15 50.0 ± 3.0 0.106 
    Head circumference (cm) 15 34.5 ± 1.3 15 34.1 ± 1.4 0.372 
    APGAR score (1 min)  15 8.0 ± 1.5 15 7.7 ± 2.1 0.695 
    APGAR score (5 min)  15 9.3 ± 0.7 15 9.0 ± 1.0 0.405 
 
Cord plasma measurements 
    
 
    Glucose (mM) 13 5.3 ± 0.9 15 5.4 ± 1.3 0.684 
    Insulin (pmol/L) 12 26.5 ± 24.4 14 36.6 ± 29.3 0.198 
    Total cholesterol (mM) 13 1.7 ± 0.3  13 1.6 ± 0.4  0.789 
    Triglycerides (mM) 13 0.6 ± 0.4 15 0.4 ± 0.2 0.151 
    Non-esterified fatty acids (mM) 14 0.4 ± 0.3 15 0.4 ± 0.2 0.410 
 
Abbreviation: GDM, gestational diabetes mellitus; Chi-square, t-tests were used to test statistical differences 
between the groups. p value in bold is significant. Data presented are mean ± standard error. 
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Table 2 : Cord plasma fatty acid concentration in phospholipids and non-esterified fatty acids from newborns 
of mothers with GDM vs. controls. 
Abbreviation: GDM, gestational diabetes mellitus; NA, not available; ND, Not detected. Data presented are 
mean ± standard error; p values in bold are significant. Data presented are mean ± standard error.  
 
 
 
 
Phospholipids 
  
Non-esterified fatty acids 
 
Fatty acid 
(mg/dl) 
Controls (n = 13) GDM (n = 13) p value 
 
Controls (n = 15) GDM (n = 9) p value 
C14:0 3.0 ± 1.6 2.3 ± 1.0 0.182 
 
3.1 ± 2.4 2.1 ± 1.8 0.308 
C16:0 273.1 ± 73.8 229.2 ± 37.0 0.050 
 
64.2 ± 44.6 38.4 ± 20.3 0.098 
C18:0 134.4 ± 18.7 124.7 ± 19.0 0.197 
 
33 ± 19.4 25.6 ± 9.9 0.272 
C16:1 n-7 8.1 ± 3.7 5.9 ± 2.0 0.050 
 
8.7 ± 10.2 3.6 ± 5.0 0.153 
C18:1 n-9 75.7 ± 19.5 61.7 ± 13.0 0.030 
 
46.5 ± 57.1 25.1 ± 31.4 0.294 
C18:1 n-7 24.0 ± 6.2 19.6 ± 3.9 0.030 
 
5.8 ± 6.6 2.8 ± 3.7 0.210 
C18:3 n-3 ND ND NA 
 
0.5 ± 0.5 0.3 ± 0.3 0.260 
C20:5 n-3 2.7 ± 1.0 2.6 ± 1.2 0.802 
 
0.8 ± 2.3 1.0 ± 3.2 0.936 
C22:5 n-3 4.0 ± 1.4 3.2 ± 2.0 0.300 
 
0.4 ± 0.8 ND NA 
C22:6 n-3 50.5 ± 16.6 43.0 ± 12.1 0.178 
 
2.9 ± 4.1 1.3 ± 1.9 0.255 
C18:2 n-6 69.7 ± 19.3 61.4 ± 15.1 0.216 
 
22.7 ± 21.8 10.6 ± 11.6 0.124 
C20:3 n-6 49.0 ± 10.7 40.4 ± 8.3 0.023 
 
1.3 ± 1.8 0.9 ± 1.3 0.571 
C20:4 n-6 180.2 ± 57.2 150.4 ± 29.1 0.078 
 
6.5 ± 8.5  3.1 ± 4.8 0.266 
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